留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

妇科肿瘤研究进展

彭澎 李雷

彭澎, 李雷. 妇科肿瘤研究进展[J]. 协和医学杂志, 2016, 7(1): 37-43. doi: 10.3969/j.issn.1674-9081.2016.01.008
引用本文: 彭澎, 李雷. 妇科肿瘤研究进展[J]. 协和医学杂志, 2016, 7(1): 37-43. doi: 10.3969/j.issn.1674-9081.2016.01.008

妇科肿瘤研究进展

doi: 10.3969/j.issn.1674-9081.2016.01.008
详细信息
    通讯作者:

    彭澎 电话:010-69156204, E-mail:pengp1999@163.com

  • 中图分类号: R737.3

  • 编者按:
    Journal Club译为“文献俱乐部”,通常是指一群人按照某个主题共同研读若干篇专业领域的文献。Journal Club发端于西方,有记录最早的“文献俱乐部”是英国外科医生James Paget于19世纪中期在伦敦St Bartholomew's医院旁的一间小屋聚集了一群医生定期阅读文献。著名医学家William Osler于1875年在加拿大蒙特利尔的麦吉尔大学(McGill University)建立了第一个正式的文献俱乐部。此后,文献俱乐部在全世界的大学和研究机构成为一种普遍的知识传播和更新方式。
  • [1] Sundström K, Ploner A, Arnheim-Dahlström L, et al. Interactions between high- and low-risk HPV types reduce the risk of squamous cervical cancer[J]. J Natl Cancer Inst, 2015, 107:djv185. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=3607757bdc723584c722b125c234c224
    [2] Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment[J]. JAMA Oncol, 2015, 1:943-951. doi:  10.1001/jamaoncol.2015.2690
    [3] Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population[J]. J Clin Oncol, 2015, 33:2901-2907. doi:  10.1200/JCO.2015.61.2408
    [4] Hung R, J Ulrich CM, Goode EL, et al. Cross cancer genomic investigation of inflammation pathway for five common cancers: lung, ovary, prostate, breast, and colorectal cancer[J]. J Natl Cancer Inst, 2015, 107:djv246. doi:  10.1093/jnci/djv246
    [5] Dorton BJ, Vitonis AF, Feldman S. Comparing cervical cytology and histology among human papillomavirus-vaccinated and -unvaccinated women in an academic colposcopy clinic[J]. Obstet Gynecol, 2015, 126:785-791. doi:  10.1097/AOG.0000000000001011
    [6] Vandeperre A, Van Limbergen E, Leunen K, et al. Para-aortic lymph node metastases in locally advanced cervical cancer: Comparison between surgical staging and imaging[J]. Gynecol Oncol, 2015, 138:299-303. doi:  10.1016/j.ygyno.2015.05.021
    [7] Arnaboldi P, Santoro L, Mazzocco K, et al. The paradox of pelvic exenteration: the interaction of clinical and psychological variables[J]. Int J Gynecol Cancer, 2015, 25:1534-1540. doi:  10.1097/IGC.0000000000000523
    [8] Kohler C, Mustea A, Marnitz S, et al. Perioperative morbidity and rate of upstaging after laparoscopic staging for patients with locally advanced cervical cancer: results of a prospective randomized trial[J]. Am J Obstet Gynecol, 2015, 213:503 e1-e7. doi:  10.1016/j.ajog.2015.05.026
    [9] Chiantera V, Vizzielli G, Lucidi A, et al. Laparoscopic radical hysterectomy in cervical cancer as total mesometrial resection (L-TMMR): a multicentric experience[J]. Gynecol Oncol, 2015, 139:47-51. doi:  10.1016/j.ygyno.2015.07.010
    [10] Todo Y, Yamazaki H, Takeshita S, et al. Close relationship between removal of circumflex iliac nodes to distal external iliac nodes and postoperative lower-extremity lymphedema in uterine corpus malignant tumors[J]. Gynecol Oncol, 2015, 139:160-164. doi:  10.1016/j.ygyno.2015.07.003
    [11] Aghajanian C, Goff B, Nycum LR, et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer[J]. Gynecol Oncol, 2015, 139:10-16. doi:  10.1016/j.ygyno.2015.08.004
    [12] Buda A, Lissoni AA, Floriani I, et al. Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: validity of pathological response as surrogate endpoint of survival[J]. Int J Gynecol Cancer, 2015, 25:1468-1475. doi:  10.1097/IGC.0000000000000515
    [13] Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials[J]. Lancet Oncol, 2015, 16:1079-1089. doi:  10.1016/S1470-2045(15)00035-2
    [14] Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial[J]. Lancet Oncol, 2015, 16:1071-1078. doi:  10.1016/S1470-2045(15)00034-0
    [15] Chu MM, Ma Y, Tse KY, et al. Cyclophosphamide, hydroxyurea, actinomycin d, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia[J]. Int J Gynecol Cancer, 2015, 25:498-503. doi:  10.1097/IGC.0000000000000383
    [16] Ho JC, Allen PK, Jhingran A, et al. Management of nodal recurrences of endometrial cancer with IMRT[J]. Gynecol Oncol, 2015, 139:40-46. doi:  10.1016/j.ygyno.2015.07.096
    [17] Ferriss JS, Java JJ, Bookman MA, et al. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study[J]. Gynecol Oncol, 2015, 139:17-22. doi:  10.1016/j.ygyno.2015.07.103
    [18] Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial[J]. Lancet Oncol, 2015, 16:928-936. doi:  10.1016/S1470-2045(15)00086-8
    [19] Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial[J]. Lancet Oncol, 2015, 16:1515-1524. doi:  10.1016/S1470-2045(15)00220-X
    [20] Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial[J]. Lancet, 2015, 386:2078-2088. doi:  10.1016/S0140-6736(15)00239-1
    [21] Chan JL, Letourneau J, Salem W, et al. Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery[J]. Gynecol Oncol, 2015, 139:141-147. doi:  10.1016/j.ygyno.2015.07.105
    [22] Melin J, Heinavaara S, Malila N, et al. Adverse Obstetric Outcomes Among Early-Onset Cancer Survivors in Finland[J]. Obstet Gynecol, 2015, 126:803-810. doi:  10.1097/AOG.0000000000001035
    [23] Felix AS, Scott McMeekin D, Mutch D, et al. Associations between etiologic factors and mortality after endometrial cancer diagnosis: The NRG Oncology/Gynecologic Oncology Group 210 trial[J]. Gynecol Oncol, 2015, 139:70-76. doi:  10.1016/j.ygyno.2015.08.022
    [24] Pol FJM, Zusterzeel PLM, van Ham MAPC, et al. Satellite lymphovascular space invasion: An independent risk factor in early stage cervical cancer[J]. Gynecol Oncol, 2015, 138:579-584. doi:  10.1016/j.ygyno.2015.06.035
    [25] Andersen CL, Eskelund CW, Siersma VD, et al. Is thrombocytosis a valid indicator of advanced stage and high mortality of gynecological cancer? [J]. Gynecol Oncol, 2015, 139:312-318. doi:  10.1016/j.ygyno.2015.09.017
  • 加载中
计量
  • 文章访问数:  1481
  • HTML全文浏览量:  652
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-12-28
  • 刊出日期:  2016-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!